Long-term Benefit in Psoriasis With Monoclonal Antibody Long-term Benefit in Psoriasis With Monoclonal Antibody

The reSURFACE 1 and 2 studies show 4-year benefits with tildrakizumab for patients with moderate to severe plaque psoriasis.Medscape Medical News

Source: Medscape Medical News Headlines - October 14, 2019 Category: Consumer Health News Tags: Dermatology News Source Type: news